IOVS Annual Reviews: Biomedical Science Suite
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2008;49:1345-1349.)
© 2008 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.07-0308
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Jiang, S.
Right arrow Articles by Sternberg, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jiang, S.
Right arrow Articles by Sternberg, P.

Associations of Plasma-Soluble Fas Ligand with Aging and Age-Related Macular Degeneration

Shunai Jiang,1,2 Siobhan E. Moriarty-Craige,1 Chun Li,3 Michael J. Lynn,4 Jiyang Cai,5 Dean P. Jones,1 and Paul Sternberg5

1From the Department of Medicine, Emory University School of Medicine, and the 4Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, Georgia; the 2Department of Ophthalmology and Visual Science, University of Louisville, Louisville, Kentucky; and the 3Department of Biostatistics and 5Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee.

PURPOSE. To evaluate the associations between plasma-soluble Fas ligand (sFasL) and age-related macular degeneration (AMD).

METHODS. Plasma samples were obtained from 230 individuals (age range, 45–85), with or without AMD. The concentrations of sFasL were determined by an enzyme-linked immunosorbent assay (ELISA). The measured sFasL levels were transformed into cubic roots and were fitted into linear regression models against AMD status, with adjustment for age and sex.

RESULTS. Plasma sFasL increased with age and AMD. There was a linear correlation between age and the cubic roots of sFasL. The plasma sFasL concentrations in non-AMD subjects ranged from 0 to 1.63 ng/mL (median, 0.69 ng/mL), whereas in patients with AMD, sFasL ranged from 0 to 2.43 ng/mL (median, 0.18 ng/mL). Between the ages of 61 and 84, the subjects with AMD had significantly higher sFasL than did the non-AMD subjects. There was a sexual dimorphism of the plasma sFasL levels. In non-AMD subjects, sFasL was lower in the females. In patients with AMD, sFasL was higher in the females.

CONCLUSIONS. An elevation of plasma sFasL with aging may play a role in the development of AMD and is a potential peripheral marker for monitoring disease progression.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Association for Research in Vision and Ophthalmology